MA27680A1 - Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1 - Google Patents

Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1

Info

Publication number
MA27680A1
MA27680A1 MA27029A MA27029A MA27680A1 MA 27680 A1 MA27680 A1 MA 27680A1 MA 27029 A MA27029 A MA 27029A MA 27029 A MA27029 A MA 27029A MA 27680 A1 MA27680 A1 MA 27680A1
Authority
MA
Morocco
Prior art keywords
neurokinin
phenyl
receptor antagonists
pyridine derivatives
pyridine
Prior art date
Application number
MA27029A
Other languages
English (en)
Inventor
Thierry Godel
Torsten Hoffmann
Heinz Stadler
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27680A1 publication Critical patent/MA27680A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA27029A 2000-08-08 2003-02-05 Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1 MA27680A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117003 2000-08-08

Publications (1)

Publication Number Publication Date
MA27680A1 true MA27680A1 (fr) 2006-01-02

Family

ID=8169466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27029A MA27680A1 (fr) 2000-08-08 2003-02-05 Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1

Country Status (37)

Country Link
US (1) US6770637B2 (fr)
EP (1) EP1309559B1 (fr)
JP (1) JP4053877B2 (fr)
KR (1) KR100518201B1 (fr)
CN (1) CN1293056C (fr)
AR (1) AR030324A1 (fr)
AT (1) ATE328871T1 (fr)
AU (2) AU1211802A (fr)
BR (1) BR0113173A (fr)
CA (1) CA2418868C (fr)
CZ (1) CZ2003684A3 (fr)
DE (1) DE60120419T2 (fr)
DK (1) DK1309559T3 (fr)
EC (1) ECSP034475A (fr)
ES (1) ES2264706T3 (fr)
GT (1) GT200100160A (fr)
HK (1) HK1076459A1 (fr)
HR (1) HRP20030055A2 (fr)
HU (1) HUP0301671A3 (fr)
IL (2) IL154079A0 (fr)
JO (1) JO2371B1 (fr)
MA (1) MA27680A1 (fr)
MX (1) MXPA03001143A (fr)
MY (1) MY128993A (fr)
NO (1) NO324841B1 (fr)
NZ (1) NZ523751A (fr)
PA (1) PA8524401A1 (fr)
PE (1) PE20020332A1 (fr)
PL (1) PL359849A1 (fr)
PT (1) PT1309559E (fr)
RU (1) RU2277087C2 (fr)
SI (1) SI1309559T1 (fr)
TW (1) TWI259180B (fr)
UY (1) UY26872A1 (fr)
WO (1) WO2002016324A1 (fr)
YU (1) YU8703A (fr)
ZA (1) ZA200300614B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
EP1688408A3 (fr) * 2002-08-08 2007-08-22 Amgen, Inc Ligands du récepteur vanilloide et leur utilisation dans des traitements
CA2493667C (fr) 2002-08-08 2010-04-27 Amgen Inc. Ligands de recepteur vanilloide et leur utilisation dans des traitements
WO2005000247A2 (fr) * 2003-06-25 2005-01-06 Smithkline Beecham Corporation Nouveaux composes
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CA2556239A1 (fr) 2004-02-11 2005-08-25 Amgen Inc. Ligands du recepteur vanilloide et leurs applications dans des traitements
ATE537830T1 (de) * 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
CN1984891B (zh) * 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089311A1 (fr) 2005-02-15 2006-08-24 Amgen Inc. Ligands des recepteurs vanilloides et leurs utilisations therapeutiques
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
AU2006279810B2 (en) * 2005-08-11 2011-10-27 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
EP2404919B1 (fr) 2005-11-08 2013-08-21 Vertex Pharmaceuticals Incorporated Composé hétérocyclique en tant qu'un modulateur de transporteurs de cassette à liaison ATP
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
PL2007756T3 (pl) 2006-04-07 2016-01-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011054773A1 (fr) 2009-11-03 2011-05-12 Glaxosmithkline Llc Nouveaux composes lactame
FR2954315B1 (fr) * 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
CA2850551A1 (fr) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Derives pyridines
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
MX357328B (es) 2011-11-08 2018-07-05 Vertex Pharma Moduladores de trasportadores de casete enlazante de atp.
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2930008A1 (fr) * 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Derive de carboxymethylpiperidine
MX2016006118A (es) 2013-11-12 2016-07-21 Vertex Pharma Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10538491B2 (en) * 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CN108712913B (zh) 2015-12-22 2022-06-24 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
CN114728906B (zh) 2019-11-15 2024-08-20 康堤医疗有限公司 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (fr) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode pour fours à arcs
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SG52217A1 (en) 1993-12-29 1998-09-28 Merck Sharp & Dohme Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
AU4885097A (en) * 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1035115B1 (fr) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
WO2000050398A2 (fr) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
AU1065801A (en) * 1999-10-14 2001-04-23 Telefonaktiebolaget Lm Ericsson (Publ) System and method of retrieving voice mail messages in a telecommunications network
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida

Also Published As

Publication number Publication date
HUP0301671A3 (en) 2010-03-29
HRP20030055A2 (en) 2005-02-28
CN1610670A (zh) 2005-04-27
KR100518201B1 (ko) 2005-10-04
SI1309559T1 (sl) 2006-10-31
CA2418868C (fr) 2010-02-02
IL154079A0 (en) 2003-07-31
PA8524401A1 (es) 2002-04-25
EP1309559B1 (fr) 2006-06-07
BR0113173A (pt) 2003-06-24
DE60120419T2 (de) 2007-06-06
JP2004506718A (ja) 2004-03-04
HUP0301671A2 (hu) 2003-08-28
MXPA03001143A (es) 2003-06-24
WO2002016324A1 (fr) 2002-02-28
AU2002212118B2 (en) 2005-12-15
ATE328871T1 (de) 2006-06-15
MY128993A (en) 2007-03-30
AU1211802A (en) 2002-03-04
KR20030022370A (ko) 2003-03-15
EP1309559A1 (fr) 2003-05-14
IL154079A (en) 2008-03-20
ES2264706T3 (es) 2007-01-16
CA2418868A1 (fr) 2002-02-28
GT200100160A (es) 2002-05-16
PL359849A1 (en) 2004-09-06
HK1076459A1 (en) 2006-01-20
AR030324A1 (es) 2003-08-20
DK1309559T3 (da) 2006-10-02
CZ2003684A3 (cs) 2003-11-12
ZA200300614B (en) 2004-04-22
RU2277087C2 (ru) 2006-05-27
US20020040040A1 (en) 2002-04-04
PE20020332A1 (es) 2002-05-10
NZ523751A (en) 2004-08-27
JO2371B1 (en) 2006-12-12
DE60120419D1 (de) 2006-07-20
TWI259180B (en) 2006-08-01
NO324841B1 (no) 2007-12-17
US6770637B2 (en) 2004-08-03
UY26872A1 (es) 2002-01-31
PT1309559E (pt) 2006-10-31
ECSP034475A (es) 2003-03-31
CN1293056C (zh) 2007-01-03
YU8703A (sh) 2006-05-25
NO20030632L (no) 2003-02-07
JP4053877B2 (ja) 2008-02-27
NO20030632D0 (no) 2003-02-07

Similar Documents

Publication Publication Date Title
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
MA26971A1 (fr) Derives de phenylethenyle ou de phenylethinyle en tant qu'antagonistes de recepteur de glutamate
MA26933A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.
FR17C0008I1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
NO20031474L (no) Metabotropiske glutamatreseptorantagonister
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
MA27679A1 (fr) Derives d'acides carboxyliques en tant qu'antagonistes ip
DZ3443A1 (fr) Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2
MA26929A1 (fr) N-oxydes en tant que promedicaments antagonistes recepteurs nk1 des derives de 4-phenyl-pyridine
MA26972A1 (fr) Derives du tetralone en tant qu'agents anti-tumeur
MA26958A1 (fr) Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip
ATE492535T1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
DE50100358D1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
ATE286018T1 (de) Biphenylderivate als neurokinin-1 antagonisten
DZ3333A1 (fr) Antagonistes de recepteurs d'il-8
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
ATE305001T1 (de) Propansäure-derivate als integrin-rezeptor- antagonisten
IS6429A (is) Indólafleiður sem MCP-1 viðtakamótlyf
FR2824826B1 (fr) Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
SE0003996D0 (sv) Receptorantagonister
DK1171419T3 (da) Biphenylderivater som antagonister til Neurokinin-1-receptoren